JW Pharma releases cancer treatment trial results
South Korea based JW Pharmaceuticals recently presented phase 1a/1b clinical trial results for CWP291, a target anticancer treatment that uses…
TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting
TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or…